Berliner Boersenzeitung - US approves updated Pfizer, Moderna shots targeting Omicron

EUR -
AED 4.245913
AFN 76.887634
ALL 93.218842
AMD 422.094755
AOA 1060.176801
ARS 1724.882567
AUD 1.638747
AWG 2.082489
AZN 1.97002
BAM 1.955776
BBD 2.321671
BDT 142.688227
BHD 0.434695
BIF 3451.157116
BMD 1.156136
BND 1.477082
BOB 13.69983
BRL 5.876989
BSD 1.152686
BTN 109.688637
BWP 15.558807
BYN 3.432357
BYR 22660.258427
BZD 2.318271
CAD 1.61333
CDF 2615.761404
CHF 0.934181
CLF 0.026836
CLP 1056.199727
CNY 7.801146
CNH 7.796152
COP 3633.55485
CRC 523.993489
CUC 1.156136
CUP 30.637594
CVE 110.26363
CZK 24.258158
DJF 205.267449
DKK 7.477932
DOP 67.289164
DZD 152.967099
EGP 57.293288
ERN 17.342035
ETB 186.049588
FJD 2.553384
FKP 0.8566
GBP 0.856968
GEL 3.017966
GGP 0.8566
GHS 13.526832
GIP 0.8566
GMD 84.980421
GNF 10123.874202
GTQ 8.794891
GYD 241.157003
HKD 9.067746
HNL 30.895616
HRK 7.536622
HTG 150.718127
HUF 363.096405
IDR 20580.370421
ILS 3.468234
IMP 0.8566
INR 110.076256
IQD 1509.981237
IRR 1590322.371805
ISK 142.598215
JEP 0.8566
JMD 183.057725
JOD 0.819746
JPY 182.445186
KES 149.158147
KGS 101.104505
KHR 4681.941823
KMF 492.514185
KRW 1627.712241
KWD 0.356853
KYD 0.960588
KZT 540.233287
LAK 26025.676609
LBP 103223.017367
LKR 386.635196
LRD 208.057415
LSL 18.726567
LTL 3.413768
LVL 0.699335
LYD 7.331909
MAD 10.743067
MDL 20.044751
MGA 4918.938878
MKD 61.524236
MMK 2427.596601
MNT 4159.0218
MOP 9.314584
MRU 46.338424
MUR 54.419742
MVR 17.862733
MWK 1998.775164
MXN 19.811945
MYR 4.728715
MZN 73.882892
NAD 18.726567
NGN 1577.963717
NIO 42.419473
NOK 10.99759
NPR 175.501819
NZD 1.961547
OMR 0.442445
PAB 1.152686
PEN 3.903651
PGK 5.093937
PHP 70.183258
PKR 320.014324
PLN 4.299905
PYG 6853.914834
QAR 4.213648
RON 5.244583
RSD 117.338542
RUB 94.679224
RWF 1694.978938
SAR 4.345489
SBD 9.325039
SCR 16.705092
SDG 694.263698
SEK 10.961095
SGD 1.477661
SLE 28.445176
SOS 658.791814
SRD 43.778814
STD 23929.673396
STN 24.499696
SVC 10.085875
SZL 18.722767
THB 38.210709
TJS 10.633568
TMT 4.058036
TND 3.386358
TRY 55.144784
TTD 7.812903
TWD 37.286072
TZS 3051.762079
UAH 51.625959
UGX 4293.946644
USD 1.156136
UYU 46.399423
UZS 13785.828699
VES 873.763846
VND 30295.956222
VUV 138.059733
WST 3.160483
XAF 655.948849
XAG 0.018188
XAU 0.000266
XCD 3.124515
XCG 2.077474
XDR 0.81579
XOF 655.948849
XPF 119.331742
YER 275.626884
ZAR 18.667336
ZMK 10406.612213
ZMW 21.75673
ZWL 372.275202
  • CMSC

    0.0240

    21.744

    +0.11%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • BCC

    2.3400

    86.6

    +2.7%

  • BCE

    -0.0200

    22.75

    -0.09%

  • RIO

    1.4500

    101.1

    +1.43%

  • JRI

    0.1500

    12.81

    +1.17%

  • GSK

    0.7900

    52.96

    +1.49%

  • BTI

    0.6000

    59.33

    +1.01%

  • NGG

    0.4700

    80.88

    +0.58%

  • AZN

    1.4100

    161.42

    +0.87%

  • BP

    -0.6000

    41.63

    -1.44%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • VOD

    0.1900

    16.19

    +1.17%

  • RELX

    0.0485

    35.52

    +0.14%

  • RYCEF

    0.2300

    20.85

    +1.1%

US approves updated Pfizer, Moderna shots targeting Omicron
US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File

US approves updated Pfizer, Moderna shots targeting Omicron

US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.

Text size:

The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.

This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.

Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.

The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.

CDC director Rochelle Walensky will be in charge of giving the final green light.

The new versions of the vaccines could potentially be available in the United States as early as next week.

"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.

The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.

In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.

Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.

(H.Schneide--BBZ)